Agilent Technologies, Inc. (NYSE:A) Receives $140.08 Consensus PT from Analysts

Agilent Technologies, Inc. (NYSE:A) has been assigned a consensus recommendation of “Moderate Buy” from the twelve brokerages that are covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $140.0833.

A number of research analysts recently commented on A shares. Wells Fargo & Company boosted their price objective on shares of Agilent Technologies from $140.00 to $150.00 and gave the company an “overweight” rating in a research report on Monday. Wall Street Zen downgraded shares of Agilent Technologies from a “buy” rating to a “hold” rating in a research report on Friday, September 5th. TD Cowen boosted their price objective on shares of Agilent Technologies to $150.00 and gave the company a “buy” rating in a research report on Thursday, May 29th. JPMorgan Chase & Co. lowered their price objective on shares of Agilent Technologies from $160.00 to $155.00 and set an “overweight” rating on the stock in a research report on Thursday, May 29th. Finally, Robert W. Baird boosted their price objective on shares of Agilent Technologies from $141.00 to $142.00 and gave the company an “outperform” rating in a research report on Thursday, August 28th.

Insider Buying and Selling

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,508 shares of the business’s stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $117.44, for a total value of $177,099.52. Following the completion of the sale, the chief executive officer directly owned 37,448 shares of the company’s stock, valued at $4,397,893.12. The trade was a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Institutional Trading of Agilent Technologies

Institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. raised its stake in Agilent Technologies by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 33,997,845 shares of the medical research company’s stock valued at $4,012,086,000 after purchasing an additional 589,219 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in Agilent Technologies by 10.7% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 13,227,387 shares of the medical research company’s stock valued at $1,560,964,000 after purchasing an additional 1,273,994 shares during the last quarter. Geode Capital Management LLC raised its stake in Agilent Technologies by 1.6% during the 2nd quarter. Geode Capital Management LLC now owns 7,319,530 shares of the medical research company’s stock valued at $860,137,000 after purchasing an additional 115,183 shares during the last quarter. Generation Investment Management LLP raised its stake in Agilent Technologies by 15.9% during the 2nd quarter. Generation Investment Management LLP now owns 5,775,860 shares of the medical research company’s stock valued at $681,609,000 after purchasing an additional 792,304 shares during the last quarter. Finally, Pictet Asset Management Holding SA raised its stake in shares of Agilent Technologies by 2.5% in the 1st quarter. Pictet Asset Management Holding SA now owns 5,341,870 shares of the medical research company’s stock valued at $624,888,000 after buying an additional 128,131 shares in the last quarter.

Agilent Technologies Stock Up 0.7%

A stock opened at $127.67 on Tuesday. Agilent Technologies has a 52 week low of $96.43 and a 52 week high of $153.84. The company has a market capitalization of $36.19 billion, a price-to-earnings ratio of 29.97, a price-to-earnings-growth ratio of 3.94 and a beta of 1.24. The firm’s 50-day moving average is $120.19 and its two-hundred day moving average is $115.94. The company has a current ratio of 2.25, a quick ratio of 1.71 and a debt-to-equity ratio of 0.53.

Agilent Technologies (NYSE:A) last released its earnings results on Wednesday, August 27th. The medical research company reported $1.37 EPS for the quarter, hitting analysts’ consensus estimates of $1.37. The business had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The business’s revenue for the quarter was up 10.1% on a year-over-year basis. During the same period in the previous year, the firm earned $1.32 EPS. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. On average, analysts forecast that Agilent Technologies will post 5.58 earnings per share for the current fiscal year.

Agilent Technologies Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 22nd. Shareholders of record on Tuesday, September 30th will be given a $0.248 dividend. This represents a $0.99 annualized dividend and a yield of 0.8%. The ex-dividend date of this dividend is Tuesday, September 30th. Agilent Technologies’s payout ratio is currently 23.24%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.